Dr. Keith J. Dunn (PharmD, BCPS, AAHIVE) is a seasoned professional in the field of pharmaceuticals, with expertise in HIV, HCV, tuberculosis, COVID-19 and medical affairs. With a career spanning over a decade, he has held various leadership roles in global pharmaceutical companies, contributing significantly to the advancement of HIV treatment and research. Currently serving as the Sr Director of Phase IV Research for HIV Treatment at Gilead Sciences, Dr. Dunn focuses on driving innovation and excellence for late-stage HIV treatment strategies worldwide with a focus on long-acting treatments. Before his current role, Dr. Dunn held several key positions at Janssen Scientific Affairs, demonstrating his commitment to advancing medical knowledge and improving patient outcomes through research related to rapid initiation of treatment, treatment adherence, comorbidities, and health economics. Dr. Dunn earned his Doctorate of Pharmacy from Northeastern University in Boston, and completed post-graduate training in HIV/Infectious Disease at Boston Medical Center. His dedication to ongoing learning and professional development is evident in his pursuit of additional qualifications, including a Diploma in Vaccinology from Institut Pasteur as well as board certification in Pharmacotherapy and expert certification from the American Academy of HIV Medicine.
